Aptose Biosciences Inc (OTCPK:APTOF) Stock News, Headlines & Updates
Aptose Biosciences Inc Stock News from GuruFocus
- 1
Jul 15, 2025
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
GlobeNewswire • 5:00pm
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML | APTOF Stock News
GuruFocus News • 4:18pm
Jun 30, 2025
Aptose Announces Deferral of Interest Payment | APTOF Stock News
GuruFocus News • 4:16pm
Jun 20, 2025
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML | APTOF Stock News
GuruFocus News • 7:00am
Jun 17, 2025
Aptose Provides Corporate Updates | APTOF Stock News
GuruFocus News • 7:00am
Jun 12, 2025
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress | APTOF Stock News
GuruFocus News • 11:16am
May 27, 2025
Aptose Announces Results from Annual and Special Meeting of Shareholders | APTOF Stock News
GuruFocus News • 5:15pm
Aptose Announces Results from Annual and Special Meeting of Shareholders
GlobeNewswire • 5:00pm
May 20, 2025
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee | APTOF Stock N
GuruFocus News • 6:49am
May 14, 2025
- 1
Show
Entries
Headlines
Total 0- 1
No recent news